Abnormal Serum Biochemical Results and Mitochondrial Damage of Lymphocytes in Patients with Schizophrenia and SARS-CoV-2 Infection: A Retrospective Study
Qiao Zhang,Lei Shi,Yanping Lin,Huirong Dai,Yixuan Bai,Pan You
DOI: https://doi.org/10.2147/ndt.s462496
IF: 2.989
2024-06-21
Neuropsychiatric Disease and Treatment
Abstract:Qiao Zhang, 1, &ast Lei Shi, 1, &ast Yanping Lin, 2, &ast Huirong Dai, 1 Yixuan Bai, 1 Pan You 1 1 Xiamen Xianyue Hospital, Xianyue Hospital Affiliated to Xiamen Medical College, Fujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen, Fujian, 361012, People's Republic of China; 2 The Third Hospital of Xiamen, Xiamen, Fujian, 361100, People's Republic of China &astThese authors contributed equally to this work Correspondence: Pan You, Xiamen Xianyue Hospital, Xianyue Hospital Affiliated to Xiamen Medical College, Fujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen, Fujian, 361012, People's Republic of China, Tel/Fax +86-592-5392620, Email Purpose: In this study, we investigated the differences in clinical biochemical values and mitochondrial mass between schizophrenia patients with and without COVID-19, so as to provide assistance to the treatment and management of COVID-19 positive patients with schizophrenia. Patients and methods: We undertook an exploratory, retrospective review of patient data from Dec. 6, 2022, to Jan. 31, 2023. A total of 1696 inpatients with psychosis (921 schizophrenia patients and 775 diagnosed with other mental diseases) during this period were identified. Finally, 60 schizophrenia patients were enrolled in our study, and 20 of them were infected with syndrome coronavirus 2 (SARS-CoV-2). The serum biochemical levels and single-cell mitochondrial mass (SCMM) of the T lymphocytes of all schizophrenia patients were analyzed. Results: The serum levels of aspartate aminotransferase (AST), alkaline phosphatase (ALP), creatinine (Cr) and lactate dehydrogenase (LDH) were significantly higher in schizophrenia patients with COVID-19 (SCZ-C) group. In addition, the SCZ-C group showed lower CD3 + , CD3 + CD4 + and CD3 + CD8 + cell counts and higher SCMM of T lymphocytes compared to SCZ group. Furthermore, positive correlations were found between the T-cell subpopulation counts and positive symptom scores on the Positive and Negative Syndrome Scale (PANSS). Conclusion: Our study findings showed that schizophrenia patients with COVID-19 have a phenotype of mitochondrial damage in T lymphocytes and higher serum levels of AST, ALP, Cr and LDH, which might provide evidence for treating individuals with schizophrenia during subsequent spread of infectious disease. Keywords: biochemical characteristics, lymphocyte, mitochondrial damage, COVID-19, schizophrenia COVID-19 caused by SARS-CoV-2 infection has been raging worldwide since January 2020, bringing major challenges to public health and medical communities around the world. 1 Although the pathogenicity of the Omicron variant is considered to be significantly attenuated, the COVID-19 pandemic remains a worldwide public health crisis. 2,3 Several studies revealed that the incidence of COVID-19 was higher in schizophrenia patients than in those without psychiatric diagnoses. 4,5 Schizophrenia (SCZ) is a chronic, complex and disabling psychiatric disorder that is caused by genetic and/or environmental disruption of brain development. Previous studies have concluded that the season of birth is associated with the development of schizophrenia. 6,7 About one-third of schizophrenia patients exhibit treatment resistance features and do not respond adequately to conventional antipsychotic medication. 8,9 Protecting the mental health of these patients is therefore important not only for their own long-term health but also for controlling the pandemic. 10,11 Coronavirus infection itself may exacerbate symptoms in people with schizophrenia, as coronaviruses may be associated with symptoms of psychosis through an immune-related mechanism. 12 It can be said that COVID‐19 can cause several changes in the human immune system that are known possible etiologies of schizophrenia. 11 Previous studies have shown that COVID-19 has various psychosocial effects on schizophrenia patients. 4,13,14 At the same time, SARS-CoV-2 infection might present as liver injury, kidney injury, cardiac failure and mitochondriopathy. 15–19 Besides, mitochondrial therapy can be used to alleviate neurological complications during the COVID-19 pandemic. 20 However, there is still a lack of clinical data on whether mitochondria are therapeutic targets for schizophrenia patients with SARS-CoV-2 infection. To effectively prioritize resources for schizophrenia patients, the identification of clinical and laboratory biochemical markers is urgently needed. -Abstract Truncated-
psychiatry,clinical neurology